Advertisement

Topics

Genentech signs deal with Parvus to tackle inflammatory diseases

06:39 EDT 17 May 2019 | pharmaphorum

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease. The companies have not disclosed the upfront paymen...

Original Article: Genentech signs deal with Parvus to tackle inflammatory diseases

NEXT ARTICLE

More From BioPortfolio on "Genentech signs deal with Parvus to tackle inflammatory diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...